Advertisement

Brachytherapy pp 221-234 | Cite as

Breast: Hungarian Experience and European Trend

  • Csaba PolgárEmail author
Chapter

Abstract

Before the era of breast-conserving therapy, BT implants were used to treat large inoperable breast tumors. Later interstitial BT has been used to deliver an additional dose to the tumor bed after BCS and WBI. Based on the obvious dosimetric advantages of interstitial breast implants (over external beam techniques) supported by the encouraging results of modern boost series utilizing stepping-source afterloading technology, multicatheter HDR/PDR BT remains a standard treatment option for boosting the tumor bed after BCS and WBI.

APBI is an attractive treatment approach with considerable advantages over conventional WBI opening new prospects for interstitial breast BT. Contemporary APBI trials using interstitial BT with strict patient selection criteria resulted in an annual LR rate <1%.

Development of new standards for 3D CT image-based BT treatment planning together with the implementation of inverse dose planning will further improve the conformity of dose distribution delivered by multicatheter implants maximizing the ballistic advantage of interstitial breast BT.

Keywords

Breast-conserving therapy Radiotherapy Brachytherapy Accelerated partial breast irradiation Tumor bed boost 

References

  1. 1.
    Forquet A, Campana F, Mosseri V, et al. Iridium-192 versus cobalt-60 boost in 3-7 cm breast cancer treated by irradiation alone: final results of a randomized trial. Radiother Oncol. 1995;34:114–20.CrossRefGoogle Scholar
  2. 2.
    Polgar C, Fodor J, Major T, et al. The role of boost irradiation in the conservative treatment of stage I-II breast cancer. Pathol Oncol Res. 2001;7:241–50.CrossRefPubMedGoogle Scholar
  3. 3.
    Polgár C, Major T. Breast brachytherapy: interstitial breast brachytherapy. In: Montemaggi P, Trombetta L, Brady LW, editors. Brachytherapy: an international perspective. Cham (Switzerland): Springer International Publishing; 2016. p. 145–67.CrossRefGoogle Scholar
  4. 4.
    van Limbergen E. Indications and technical aspects of brachytherapy in breast conserving treatment of breast cancer. Cancer Radiother. 2007;7:107–20.CrossRefGoogle Scholar
  5. 5.
    Polgar C, Major T. Current status and perspectives of brachytherapy for breast cancer. Int J Clin Oncol. 2009;14:7–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.CrossRefPubMedGoogle Scholar
  7. 7.
    Bartelink H, Maingon P, Weltens C, et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 2015;16:47–56.CrossRefPubMedGoogle Scholar
  8. 8.
    Polgar C, Fodor J, Orosz Z, et al. Electron and high dose rate brachytherapy boost in the conservative treatment of stage I-II breast cancer. First results of the randomized Budapest boost trial Strahlenther Onkol. 2002;178:615–23.PubMedGoogle Scholar
  9. 9.
    Polgar C, Fodor J, Orosz Z, et al. Electron and brachytherapy boost in the conservative treatment of stage I-II breast cancer: 5-year results of the randomized Budapest boost trial. Radiother Oncol. 2002;64(Suppl. 1):S15.Google Scholar
  10. 10.
    Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15:963–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Moreno F, Guedea F, Lopez J, et al. External beam irradiation plus 192Ir implant after breast-preserving surgery in women with early breast cancer. Int J Radiat Oncol Biol Phys. 2000;48:757–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Touboul E, Belkacemi Y, Lefranc JP, et al. Early breast cancer: influence of type of boost (electron vs iridium-192 implant) on local control and cosmesis after conservative surgery and radiation therapy. Radiother Oncol. 1995;34:105–13.CrossRefPubMedGoogle Scholar
  13. 13.
    Guinot JL, Baixauli-Perez C, Soler P, et al. High-dose-rate brachytherapy boost effect on local tumor control in young women with breast cancer. Int J Radiat Oncol Biol Phys. 2015;91:165–71.CrossRefPubMedGoogle Scholar
  14. 14.
    Guinot JL, Roldan S, Maronas M, et al. Breast-conservative surgery with close or positive margins: can the breast be preserved with high-dose-rate brachytherapy boost? Int J Radiat Oncol Biol Phys. 2007;68:1381–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Hammer J, Seewald DH, Track C, et al. Breast cancer: primary treatment with external-beam radiation therapy and high-dose-rate iridium implantation. Radiology. 1994;193:573–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Henriquez I, Guix B, Tello JI, et al. Long term results of high-dose-rate (HDR) brachytherapy boost in preserving-breast cancer patients: the experience of radiation oncology medical institute (IMOR) of Barcelona. Radiother Oncol. 2001;60(Suppl. 1):S11.Google Scholar
  17. 17.
    Knauerhase H, Strietzel M, Gerber B, et al. Tumor location, interval between surgery and radiotherapy, and bosst technique influence local control after breast-conserving surgery and radiation: retrospective analysis of monoinstitutional long-term results. Int J Radiat Oncol Biol Phys. 2008;72:1048–55.CrossRefPubMedGoogle Scholar
  18. 18.
    Neumanova R, Petera J, Frgala T, et al. Long-term outcome with interstitial brachytherapy boost in the treatment of women with early-stage breast cancer. Neoplasma. 2008;54:413–23.Google Scholar
  19. 19.
    Polgar C, Jánváry L, Major T, et al. The role of high-dose-rate brachytherapy boost in breast-conserving therapy: long-term results of the Hungarian National Institute of oncology. Rep Pract Oncol Radiother. 2010;15:1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Resch A, Pötter R, van Limbergen E, et al. Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer. Radiother Oncol. 2002;63:47–58.CrossRefPubMedGoogle Scholar
  21. 21.
    Fentiman IS, Deshmane V, Tong D, et al. Caesium137 implant as sole radiation therapy for operable breast cancer: a phase II trial. Radiother Oncol. 2004;71:281–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Fentiman IS, Poole C, Tong PJ, et al. Iridium implant treatment without external radiotherapy for operable breast ancer: a pilot study. Eur J Cancer. 1991;27:447–50.CrossRefPubMedGoogle Scholar
  23. 23.
    Fentiman IS, Poole C, Tong D, et al. Inadequacy of iridium implant as a sole radiation treatment for operable breast cancer. Eur J Cancer. 1996;32A:608–11.CrossRefPubMedGoogle Scholar
  24. 24.
    Póti Z, Nemeskéri C, Fekésházi A, et al. Partial breast irradiation with interstitial 60Co brachytherapy results in frequent grade 3 or 4 toxicity. Evidence based on a 12-year follow-up of 70 patients. Int J Radiat Oncol Biol Phys. 2004;58:1022–33.CrossRefPubMedGoogle Scholar
  25. 25.
    Johansson B, Karlsson L, Liljegren G, et al. Pulsed dose rate brachytherapy as the sole adjuvant radiotherapy after breast-conserving surgery of T1-T2 breast cancer: first long time results from a clinical study. Radiother Oncol. 2009;90:30–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Polgar C, Fodor J, Major T, et al. Breast-conserving therapy with partial or whole breast irradiation: ten-year results of the Budapest randomized trial. Radiother Oncol. 2013;108:197–202.CrossRefPubMedGoogle Scholar
  27. 27.
    Polgar C, Major T, Fodor J, et al. HDR brachytherapy alone versus whole breast radiotherapy with or without tumor bed boost after breast conserving surgery: seven-year results of a comparative study. Int J Radiat Oncol Biol Phys. 2004;60:1173–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Polgar C, Major T, Fodor J, et al. Accelerated partial breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother Oncol. 2010;94:274–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Strnad V, Hildebrandt G, Pötter R, et al. Accelerated partial breast irradiation: 5-year results of the German-Austrian multicenter phase II trial using interstitial multicatheter brachytherapy alone after breast-conserving surgery. Int J Radiat Oncol Biol Phys. 2011;80:17–24.CrossRefPubMedGoogle Scholar
  30. 30.
    Strnad V, Ott OJ, Hildebrandt G, et al. Accelerated partial breast irradiation (APBI) using sole interstitial multicatheter brachytherapy versus whole breast irradiation with boost after breast conserving surgery for low risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised phase 3 non-inferiority trial. Lancet. 2016;387:229–38.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Polgar C, van Limbergen E, Pötter R, et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie – European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast Cancer working group based on clinical evidence (2009). Radiother Oncol. 2010;94:264–73.CrossRefPubMedGoogle Scholar
  32. 32.
    Major T, Gutiérrez C, Guix B, et al. Recommendations from GEC ESTRO breast Cancer working group (II): target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving open cavity surgery. Radiother Oncol. 2016;118:199–204.CrossRefPubMedGoogle Scholar
  33. 33.
    Major T, Polgar C. Treatment planning for multicatheter interstitial brachytherapy of breast cancer - from Paris system to anatomy-based inverse planning. J Contemp Brachytherapy. 2017;9:89–98.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Major T, Polgar C, Lövey K, et al. Dosimetric characteristics of accelerated partial breast irradiation with CT image-based multicatheter interstitial brachytherapy: a single institution’s experience. Brachytherapy. 2011;10:421–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Rodríguez Pérez A, Samper Ots PM, López Carrizosa MC, et al. Early-stage breast cancer conservative treatment: high-dose-rate brachytherapy boost in a single fraction of 700 cGy to the tumour bed. Clin Transl Oncol. 2012;14:362–8.CrossRefPubMedGoogle Scholar
  36. 36.
    Polgar C, Major T, Strnad V, et al. What can we conclude from the results of an out-of-date breast brachytherapy study? In regard to Póti Z, Nemeskéri C, Fekeshazy a, et al. (Int J Radiat Oncol biol Phys 2004;58:1022-1033). Int J Radiat Oncol Biol Phys. 2004;60:342–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Aristei C, Maranzano E, Lancelotta V, et al. Partial breast irradiation with interstitial multi-catheter high-dose-rate brachytherapy. Long-term results of a phase II prospective study. Radiother Oncol. 2017;124:208–13.CrossRefPubMedGoogle Scholar
  38. 38.
    Genebes C, Chand ME, Gal J, et al. Accelerated partial breast irradiation in the elderly: 5-year results of high-dose rate multi-catheter brachytherapy. Radiat Oncol. 2014;9:115.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Polgar C, Major T, Fodor J, et al. Accelerated partial breast irradiation with multicatheter brachytherapy: 15-year results of a phase II clinical trial. Acta Medica Marisiensis. 2011;57:717–20.Google Scholar
  40. 40.
    Polgar C, Ott OJ, Hildebrandt G, et al. Late side-effects and cosmetic results of accelerated partial breast irradiation using interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, phase 3 trial. Lancet Oncol. 2017;18:259–68.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Center of RadiotherapyNational Institute of OncologyBudapestHungary

Personalised recommendations